Zenas BioPharma (ZBIO) catalysts

Upcoming FDA decisions and readouts we track for Zenas BioPharma, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 11 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Zenas BioPharma (ZBIO, listed on Nasdaq). It concerns Obexelimab (Immunoglobulin G4-related disease (IgG4-RD)).

First on the list: the PDUFA date for Obexelimab (Immunoglobulin G4-related disease (IgG4-RD)), dated 27 May 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: What a PDUFA date is, and why the FDA doesn't publish them.

Ticker: ZBIO
Next catalyst: 27 May 2027
Type: PDUFA date
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Zenas BioPharma ZBIO · Nasdaq	Obexelimab	Immunoglobulin G4-related disease (IgG4-RD)	27 May 2027 in 232d	PDUFA date	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "The BLA has a Prescription Drug User Fee Act (PDUFA) target action date of May 27, 2027." Source: 8-K exhibit 99.1, filed 13 Aug 2026 · verified 11 Sep 2026

Also due in Q2 2027

Harmony Biosciences Holdings (HRMY)PDUFA date for Pitolisant GR, 01 Apr 2027
Pharvaris N.V. (PHVS)PDUFA date for Deucrictibant IR, 23 Apr 2027
Immunome (IMNM)PDUFA date for Varegacestat, 28 Apr 2027
Axsome Therapeutics (AXSM)PDUFA date for AXS-12 (reboxetine), 01 May 2027
Context Therapeutics (CNTX)Phase 1 readout for CTIM-76, Q2 2027